Cory Collier
Corneal and Contact Management · Bradenton, FLNPI 1972911147
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Valley Contax, Inc. accounts for 99.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $26,257 and has fallen 99.6% since, to $97 in 2025. Among corneal and contact management clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 64 payments — averaging $552.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Valley Contax, Inc.$35K
- Sight Sciences, Inc.$105
- Johnson & Johnson Vision Care, Inc.$105
- Coopervision Inc.$46
- Bausch & Lomb Americas Inc.$33
- Biotissue Holdings Inc.$32
- plus $48 from 3 others
What the payments were for
- Consulting fees$14,72342%
- Speaking & faculty fees$18,53152%
- Travel & lodging$1,2414%
- Food & beverage$5582%
- Gifts$2991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$35,351 in reported general payments places this provider in the 95th percentile of 67 corneal and contact management providers in Florida.
See all corneal and contact management providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Loteprednol Etabonate | 11 | $3,321 |
| Latanoprost | 53 | $430 |
| MoxifloxacinMoxifloxacin Hcl | 11 | $167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $12 | $3,32111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 67 corneal and contact management providers in Florida.
Other corneal and contact management in Bradenton
- Roxanne Achong-CoanOcoee$171K
- Justine SiergeyOrlando$21K
- Tamara MauleBoca Raton$12K
- Kenneth MallerOakland Park$12K
- Terry van der HeydenNaples$8K
- Brian ArmitageJacksonville$8K
- Gordon PennViera$7K
- Denise Burns LegrosMelbourne$6K
- Jose ArnaoGainesville$5K
- Eric RadzwillFort Lauderdale$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.